

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
25 May 2023 (25.05.2023)



(10) International Publication Number
WO 2023/091081 A3

(51) International Patent Classification:

A61K 9/14 (2006.01) *A61P 37/00* (2006.01)
A61K 38/57 (2006.01)

(21) International Application Number:

PCT/SG2022/050819

(22) International Filing Date:

10 November 2022 (10.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202112736W 16 November 2021 (16.11.2021) SG

(71) Applicants: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10, Connexis North Tower, Singapore 138632 (SG). **NATIONAL UNIVERSITY HOSPITAL (SINGAPORE) PTE LTD** [SG/SG]; 1E Kent Ridge Road, #13-00, Singapore 119228 (SG).

(72) Inventors: **HENG, Wen Chien, Desmond**; c/o Institute of Bioprocessing Technology Institute, 20 Biopolis Way, #06-01, Singapore 138668 (SG). **NG, Say Kong**; c/o Institute of Bioprocessing Technology Institute, 20 Biopolis Way, #06-01, Singapore 138668 (SG). **ZHANG, Wei**; c/o Institute of Bioprocessing Technology Institute, 20 Biopolis Way, #06-01, Singapore 138668 (SG). **LEE, Sie Huey**; c/o Institute of Chemical and Engineering Sciences, 1 Pesek Road, Jurong Island, Singapore 627833 (SG). **TEO, Woon Pei, Jeanette**; c/o National University Hospital (Singapore) Pte Ltd., 1E Kent Ridge Road, #13-00, Singapore 119228 (SG).

(74) Agent: **CHNG, Cheryl**; China Sinda Intellectual Property Pte. Ltd., 133 Cecil Street, #12-01A Keck Seng Tower, Singapore 069535, Singapore (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

17 August 2023 (17.08.2023)

(54) Title: INHALABLE RECOMBINANT PROTEIN POWDER FORMULATION FOR TREATING GENETIC AND AUTOIMMUNE DISORDERS

(57) Abstract: The present invention relates to an inhalable dry powder formulation comprising a recombinant alpha-1-antitrypsin protein, a force control agent comprising di-leucine and tri-leucine in combination thereof, wherein the force control agent is present in an amount of at least 50% by weight of the formulation, and pharmaceutically acceptable excipients including a sodium salt and a non-reducing sugar or a sugar alcohol or a combination thereof.



WO 2023/091081 A3